MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR‐T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA. (12th June 2019) - Shouse, G.P.; Xue, T.; Herrera, A.; Siddiqi, T.; Zain, J.; Popplewell, L.; Forman, S.; Budde, E.